I'll research ZBH before writing the preview. Let me gather recent earnings materials, guidance, filings, and news.Let me read the most recent earnings materials and pull historical quarters for trend context.Now let me pull the prior-year Q2 comp figures, recent news, and stock price trend.Let me check for any recent ZBH developments (CFO search, product news) heading into the print.I have what I need. Here's the earnings preview.
Report date: Wednesday, August 5, 2026 (pre-market) · Call: 8:30 a.m. ET · Quarter ending: June 30, 2026
ZBH heads into Q2 as a "show-me" story: it is executing a large U.S. sales-force overhaul and CFO transition while trying to reaccelerate a soft U.S. Knees franchise — all against Q2 being the weakest margin quarter of the year by design. The Q1 print was a beat-and-raise that the stock nonetheless punished hard, so how management frames the back-half ramp matters more than the headline.
Q1 2026 (reported April 28) was strong on paper but poorly received. Sales were $2.087B (+9.3% reported, +2.9% organic cc), and adjusted EPS was $2.09, +15.5% — but that included a ~$0.20 tariff benefit (from the invalidation of IEEPA tariffs), of which roughly $0.10 was a one-time pull-forward from the second half. Management raised full-year adjusted EPS guidance to $8.40–$8.55 (from $8.30–$8.45) and free-cash-flow growth to 9–11%, but left revenue guidance unchanged.
The market reaction was brutal: ZBH fell from $92.59 (Apr 27) to $82.80 on the print (‑10.6%) and slid to ~$80 over the next two sessions. The sell-off reflected: (1) the low-quality, tariff-driven nature of the beat; (2) the surprise announcement that CFO Suky Upadhyay is departing; and (3) an explicit warning that Q2 operating margin would be down ~200 bps YoY — i.e., the near-term P&L gets worse before it gets better.
The stock has since clawed all the way back to ~$96 (Aug 4), roughly flat-to-up YTD, so expectations have partly reset higher going in. That raises the bar for this print.
Management explicitly guided Q2 2026 adjusted operating margin down ~200 bps vs. Q2 2025's 27.8% (→ roughly 25.8%), with Q3 then down ~50 bps sequentially. Drivers: lower gross margin (full-year guided ~71% vs. 73.0% in Q1), Paragon 28 dilution, and heavy investment in the U.S. commercial channel. The comp is unforgiving: Q2 2025 adjusted EPS was $2.07 with a 72.3% adjusted gross margin. With the tariff tailwind not recurring and margins compressing, year-over-year EPS growth should decelerate sharply from Q1's +15.5% — likely roughly flat. Watch whether they hold the ~200 bps guide or if underlying cost performance comes in better (as it did in Q1).
U.S. Knees grew just +2.2% in Q1 and +1.7% in Q2 2025, dragged by the phase-out of legacy brands (NexGen, Vanguard) toward a single Persona franchise, plus two lost accounts and a West Coast Kaiser strike. Management insists it can "do better." This is the key organic-growth swing factor — and note back-half comps get ~400 bps tougher, so investors want evidence (technology pull-through, account wins) that the ramp is real, not hoped for.
For the first time in a while, international (+2.5% organic) trailed the U.S. (+3.2%) in Q1, hit by distributor consolidation in China, the Middle East and emerging markets, plus tough comps. Management guided international back to mid-single-digit growth in H2 2026. Q2 is the check on whether that recovery is on track.
The U.S. go-to-market shift from independent 1099 reps to a dedicated/specialized channel (target: complete by end-2027) is the central strategic bet. Q1 disclosures to track for updates: - 1099 reps: 66% → below 60% - Specialized reps: ~25% → approaching/exceeding 30% - Turnover: single digits vs. a 12% ceiling target - Top 6 distributors (~40% of sales) locked in for 7+ years - Rep productivity: national avg ~7 cases/week vs. lead competitor's ~16–17, with transitioned territories moving to double-digits
Watch for continued productivity gains and whether the disruption (lost accounts) stabilizes.
On the Q1 call, management deliberately declined to raise revenue guidance despite the beat, saying it was "prudent to wait 90 days." Q2 is that moment. A revenue-guidance raise (organic cc currently 1–3%) would be a strong signal; another EPS-only raise driven by tax/buyback rather than volume would likely be viewed skeptically given the Q1 experience. Also watch the up-to-100 bps price erosion assumption (Q1 came in at just ‑40 bps).
Paul Stellato (former Controller/CAO) is interim CFO. An update on the permanent CFO search — or a hire — is a possible catalyst and a governance overhang until resolved.
Q2 FX is guided roughly neutral. On tariffs, management is assuming IEEPA stays invalidated and Section 232 tariffs are broadly mitigated via the Nairobi Protocol; the "122" tariffs are assumed intact into H2. Any change to the tariff math directly moves EPS, as Q1 demonstrated. Note the macro backdrop is noisier than usual (Middle East conflict, elevated oil/freight), though ZBH said it saw no material Q1 impact.
Two post-Q1 developments strengthen the balance-sheet/return story: ZBH raised its 2026 buyback target to $1 billion (up from the ~$750M cited on the Q1 call) and secured new $2.75B revolving credit facilities in June. Net debt was ~$7.0B at Q1. A lower share count is a modest EPS tailwind into Q2.
| Metric (Q2 2025) | Value |
|---|---|
| Net sales | $2.077B (+7.0% rep / +2.8% organic cc) |
| U.S. / Int'l organic | +2.3% / +3.4% |
| Knees organic | +1.8% (U.S. +1.7%) |
| Hips organic | +4.0% (U.S. +5.2%) |
| S.E.T. organic | +4.9% |
| Adjusted EPS | $2.07 (+3.0%) |
| Adj. gross / op margin | 72.3% / 27.8% |
| Free cash flow | $247.7M |
FY2026 guidance (as of Q1): reported revenue +2.5%–4.5%; organic cc +1%–3%; adjusted EPS $8.40–$8.55; FCF growth 9–11%.
This is a quarter where the quality and cadence of results matter more than the headline. The bull case rests on organic growth holding at ~2–3% with U.S. Knees and international both inflecting in H2, the sales-force transformation showing productivity dividends, and a clean guidance raise. The bear case: Q2 is the margin trough, the Q1 beat was tariff-flattered, U.S. Knees remains stuck, and the CFO seat is unfilled — a combination that already triggered a 10%+ sell-off last quarter despite good optics. With the stock having fully recovered to ~$96, the setup is less forgiving than it was in April, so watch for (1) any revenue-guide raise, (2) U.S. Knees acceleration, and (3) confirmation that the ~200 bps Q2 margin hit is genuinely the low point for the year.
Note: figures above are drawn from ZBH's Q1 2026 and Q2 2025 earnings releases/calls and interim 8-K disclosures; this preview reflects company guidance, not independent consensus estimates, and is not investment advice.